Global Bronchodilators Market Size (2024 - 2029)

The bronchodilators market is anticipated to experience growth due to an increase in respiratory disorders, influenced by factors such as air pollution, smoking, and infectious diseases, particularly among the elderly. The market's expansion is supported by the demand for bronchodilators, which are essential for maintaining lung function in aging populations susceptible to conditions like COPD and asthma. Despite the potential impact of new product launches and approvals, the market's growth may face challenges from the side effects associated with bronchodilator use.

Market Size of Global Bronchodilators Industry

bronchodilators market trends
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 4.70 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

bronchodilators market major players

*Disclaimer: Major Players sorted in no particular order

Bronchodilators Market Analysis

The bronchodilators market studied is expected to grow with an estimated CAGR of 4.7%, over the forecast period.

Substantial increase in the number of patients with respiratory disorders on an account of COVID-19 are projected to trigger the demand for bronchodilators across the globe. Several research studies suggest that the use of bronchodilator medications in treating COVID-19 patients can facilitate normal breathing and functional improvements. These medications are mainly useful in confirmed or suspected COVID-19 cases with reactive airway diseases. A June 2021 study published in Respiratory Medicine Journal, aimed at confirming the level of bronchodilator reversibility in SARSCoV2 patients undertaking multidisciplinary pulmonary rehabilitation after the acute phase. The study concluded that the use of bronchodilators should be considered in post-COVID-19 patients as it can encourage functional improvements in the lungs for normal breathing. However, some research studies contrast the usefulness of bronchodilators and conclude that no significant changes are observed in affected patients with minimal improvement in clinical outcomes for reducing the risk of mortality. For instance, recently, in 2021, a retrospective cohort study was carried to evaluate the association between the length of COVID-19 pneumonia patient stay in the hospitals and the use of inhaled bronchodilators in Spain. The results concluded from the study did not specify any notable health improvements among patients. As a result, the bronchodilators market is anticipated to be moderately impacted by the pandemic.

The studied market growth can be attributed to a variety of factors, such as the rising prevalence of respiratory diseases globally coupled with increased levels of air pollution, the surge in the number of smokers, and propelling incidence of infectious diseases among the elderly population significantly contributing toward the risk of developing lung disorders, and are collectively driving the market growth.

One of the key parameters responsible for the growth of the bronchodilators market is the gradual decrease in functionality of lungs along with the age of an individual. Thus, these cognitive and physical changes usually make normal breathing difficult in the elderly, thereby, driving the growth of the market. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Additionally, a rising number of product launches and approvals are expected to have a positive impact on the demand for bronchodilators within the patient population. For instance, in July 2020, EVA Pharma launched 'Inhalex', the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half. On the contrary, possible side effects such as tremors, coughs, increased heart rate, and nervousness are likely to obstruct the market growth over the forecast period.

Bronchodilators Industry Segmentation

As per the scope of the report, a bronchodilator is a type of medication used in relaxing the muscles present in the airway passages of the lungs (bronchi) and widening them for easier breathing. They decrease the resistance in the respiratory passage and increase the airflow within the lungs. The Bronchodilators Market is segmented by Drug Type (Beta-Adrenergic Bronchodilators, Xanthine Derivatives, and Anticholinergic Bronchodilators), Route of Administration (Oral, Injectable, and Nasal), Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Other Indications), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Type
Beta-Adrenergic Bronchodilators
Xanthine Derivatives
Anticholinergic Bronchodilators
By Route of Administration
Oral
Injectable
Nasal
By Indication
Asthma
Chronic Obstructive Pulmonary Disease
Other Indications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Bronchodilators Market Size Summary

The bronchodilators market is poised for growth, driven by an increasing prevalence of respiratory disorders globally, exacerbated by factors such as air pollution, smoking, and the aging population. The demand for bronchodilators is expected to rise as these medications play a crucial role in managing conditions like asthma and chronic obstructive pulmonary disease (COPD). The market's expansion is further supported by the ongoing research and development efforts, alongside the introduction of new products aimed at improving patient outcomes. Despite the potential challenges posed by side effects and varying clinical outcomes, the overall market trajectory remains positive, with significant contributions from the geriatric population who are more susceptible to respiratory issues.

In North America, particularly the United States, the bronchodilators market is expected to dominate due to the high incidence of respiratory diseases and the region's robust healthcare infrastructure. The market is characterized by intense competition, with major players like Teva Pharmaceutical Industries, Novartis, and AstraZeneca leading the charge. These companies are actively involved in product launches and collaborations to enhance their market presence. The ongoing efforts to address respiratory disorders through innovative treatments and the increasing awareness among patients are likely to sustain the market's growth momentum in the coming years.

Explore More

Global Bronchodilators Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Surge in Patient Population with Respiratory Disorders

      2. 1.2.2 Significant Rise in Environmental Pollution

      3. 1.2.3 Increasing Number of Smokers

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects of Bronchodilators

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Drug Type

      1. 2.1.1 Beta-Adrenergic Bronchodilators

      2. 2.1.2 Xanthine Derivatives

      3. 2.1.3 Anticholinergic Bronchodilators

    2. 2.2 By Route of Administration

      1. 2.2.1 Oral

      2. 2.2.2 Injectable

      3. 2.2.3 Nasal

    3. 2.3 By Indication

      1. 2.3.1 Asthma

      2. 2.3.2 Chronic Obstructive Pulmonary Disease

      3. 2.3.3 Other Indications

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Bronchodilators Market Size FAQs

The Global Bronchodilators Market is projected to register a CAGR of 4.70% during the forecast period (2024-2029)

AstraZeneca, Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International GmbH and GlaxoSmithKline plc are the major companies operating in the Global Bronchodilators Market.

Bronchodilators Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)